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Letters to the Editors
Can speckle tracking 
echocardiography detect 
subclinical left ventricular 
dysfunction in patients with 
primary Sjögren’s syndrome?
Sirs, 
In Sjögren’s syndrome (SS) distinct heart 
disease is rare (1-4), but pulmonary effusion, 
pulmonary hypertension and left ventricular 
diastolic dysfunction are frequent. 
It has been found that two-dimensional 
speckle tracking echocardiography (2-D 
STE) is more sensitive than conventional 
echocardiography in detecting sub-clinical 
ventricular dysfunction in various clinical 
disorders (5-7). 
The aim of this study was to use STE to 
evaluate left ventricular myocardial func-
tion in a cohort of patients with pSS and a 
normal ejection fraction. 
Forty-nine outpatients (7 males and 42 fe-
males; mean age 57±6.9 years), who ful-
filled the American European Consensus 
(AECG) for pSS (8) and 49 healthy volun-
teers matched in terms of the anthropomet-
ric characteristics was included in the study. 
None of the them had smoked cigarettes 
during the previous ten years.
The study was approved by local Ethics 
Committee and conducted in accordance 
with the ethical guidelines of the 1975 Hel-
sinki Declaration, and informed consent was 
obtained.
The clinical data were determined by means 
of a standardised clinical interview, and the 
pSS-related laboratory variables of erythro-
cyte sedimentation rate, WBC and platelet 
counts, and C-reactive protein levels were 
measured using routine methods.
IgM rheumatoid factor (RF), anti-nuclear 
autoantibody (ANA) levels and antibodies 
against extractable nuclear antigens (ENAs) 
including SSA, SSB were also detected. The 
CV risk profile was assessed by means of 
standard electrocardiography (ECG), con-
ventional and stress trans-thoracic echocar-
dography with coronary flow reserve (CFR) 
measurement, carotid ultrasonography and 
pulse wave velocity (PWV). Speckle track-
ing analysis was performed off-line using 
commercially available QLAB 9 software 
(Philips Medical System, USA). Two-di-
mensional images were obtained from the 
apical 4-chamber view at a high frame rate 
(70–80 frames/sec), and three cardiac cycles 
were stored in cine-loop format for off-line 
analysis in order to assess end-systolic LV 
longitudinal.
Table I shows the characteristics of the study 
population. All of the pSS patients showed 
extra-glandular systemic involvement (30% 
articular, 22% haematological, 7% cutane-
ous, 8% constitutional and 4.5% peripheral 
nerve system involvement) 30 were being 
treated with hydroxychloroquine (HCQ) 
400 mg/day, 11 with azathioprine (AZA) at 
a mean dose of 150 mg/day (range 50–200 
mg), and eight with methotrexate (MTX) at 
a mean dose of 7.5 mg/weekly. None of the 
patients showed any signs or symptoms of 
CV disease, pulmonary involvement such as 
interstitial lung disease, or any other com-
plication. 
Four patients were receiving corticosteroids 
2.5 mg/day, and three were receiving 5 mg/
day due to joint involvement relapse for 3–5 
months; three were receiving nifedipine 30 
mg/day because of Raynaud’s phenomenon. 
All of the patients were positive for ANA 
and/or RF and/or SSA or SSB, and had sig-
nificantly higher CRP and ESR values than 
the healthy controls (p<0.001 for both); 
however, there were no significant differ-
ences in heart rate, arterial blood pressure, 
age or BMI (Table I). 
The patients’ mean LVEF and E/A ra-
tios were respectively 59.11±6.35% and 
0.94±.0.24, which were not significantly 
different from those of the controls; howev-
er, although within the normal range, their 
CFR was lower (median 2.7, IQR 2.40–2.90 
vs. 3.20, IQR 3.06–3.33; p<0.0001). 
The results of the STE were significantly 
different between the two groups, with 
global longitudinal strain deformation in 
the apical 4-chamber view (Long. ε 4c) be-
ing significantly lower in the pSS patients 
(median 15.28, IQR 12.3–16.2 vs. 19.8, IQR 
19.3–20.40; p<0.0001). 
Right and left pulse wave velocity (PWV) 
(median 8.8 m/sec, IQR 7.26-10.32 vs. 6.86 
m/sec, IQR 6.66-7.10; p<0.0001), and right 
and left coronary IMT (cIMT: median 0.6 
mm, IQR 0.5–0.7 vs. 0.53 mm, IQR 0.50–
0.60; p=0.08) values were all higher in the 
pSS patients, but the differences in cIMT 
were not statistically significant. 
This study show that LV myocardial lon-
gitudinal ε, as measured by means of STE, 
was impaired in our pSS patients in the ab-
sence of any clinical evidence of CV disease 
and when the traditional echocardiographic 
parameters were still negative, thus sug-
gesting a myocardial alteration (9). We do 
not have a clear explanation for this finding 
(10), but these alterations are so small that 
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Table I. Characteristics of the study population. 
 Primary SS patients (n=49) Healthy controls (n=49) p-value
No. of females (%) 42 (85.7%) 40 (81.6%) 0.06
Age (years) 57.5 ± 6.90 59.6 ± 2.08 0.07
BMI (kg/m-2) 25.6 ± 3.77 23.69 ± 1.12 0.07
Systolic blood pressure (mmHg) 126 ± 17 125 ± 12 0.08
Diastolic blood pressure (mmHg) 82 ± 6 80 ± 8 0.08
Heart rate (bpm) 65 ± 10 68 ± 12 0.07
CRP (mg/dL-1) 7.36 ± 2.08 0.41 ± 0.09 <0.0001
ESR (mm/h-1) 23.33 ± 12.86 4.84 ± 0.24 <0.0001
Disease duration (months) 77.16 ± 34.68  
Mean values ± standard deviation (SD). 
BMI: body mass index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.
